Levy D, Walmsley P, Levenstein M
Division of Epidemiology and Preventive Medicine, Boston University School of Medicine, MA, USA.
Am Heart J. 1996 May;131(5):966-73. doi: 10.1016/s0002-8703(96)90181-7.
The Hypertension and Lipid Trial (HALT) was undertaken to assess the efficacy and safety of doxazosin, a selective alpha 1- adrenergic blocker, in patients with hypertension in a clinical practice setting. The effects of doxazosin on office blood pressure, changes in lipid profiles, and theoretic coronary disease risk were studied. In an open, noncomparative, multicenter trial, 851 patients were studied for a maximum of 16 weeks. Doxazosin significantly reduced mean sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) by 15.2/12.5 mm Hg and standing SBP and DBP by 16.1/12.7 mm Hg in the total study population (n = 807; p = 0.0001), with no significant effect on heart rate. Mean total cholesterol levels were significantly reduced by 2.7%, low-density lipoprotein cholesterol levels by 2.4%, and mean triglyceride levels by 3.4% (all p values < 0.05). High-density lipoprotein (HDL) cholesterol levels were essentially unchanged. The mean ratio of total to HDL cholesterol was significantly reduced (p < 0.05). Mean predicted 5-year coronary disease risk was significantly reduced with doxazosin therapy by 14.7% in previously untreated patients (p < 0.0001) and by 1.7% in patients who were previously receiving antihypertensive therapy (p < 0.05). The drug was well tolerated. This study demonstrates that antihypertensive therapy with doxazosin can favorably affect coronary disease risk factors and reduce predicted coronary disease risk.
高血压与血脂试验（HALT）旨在评估选择性α1肾上腺素能阻滞剂多沙唑嗪在临床实践环境中治疗高血压患者的疗效和安全性。研究了多沙唑嗪对诊室血压、血脂谱变化以及理论冠心病风险的影响。在一项开放、非对照、多中心试验中，对851例患者进行了最长16周的研究。在总研究人群（n = 807；p = 0.0001）中，多沙唑嗪使平均坐位收缩压（SBP）和舒张压（DBP）显著降低15.2/12.5 mmHg，使站立位SBP和DBP显著降低16.1/12.7 mmHg，对心率无显著影响。总胆固醇平均水平显著降低2.7%，低密度脂蛋白胆固醇水平降低2.4%，甘油三酯平均水平降低3.4%（所有p值<0.05）。高密度脂蛋白（HDL）胆固醇水平基本未变。总胆固醇与HDL胆固醇的平均比值显著降低（p < 0.05）。在未经治疗的患者中，多沙唑嗪治疗使平均预测5年冠心病风险显著降低14.7%（p < 0.0001），在先前接受抗高血压治疗的患者中降低1.7%（p < 0.05）。该药物耐受性良好。这项研究表明，多沙唑嗪抗高血压治疗可对冠心病危险因素产生有利影响，并降低预测的冠心病风险。
